{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:12:22Z","timestamp":1782256342840,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd007778","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T00:00:00Z","timestamp":1492041600000}}],"reference-count":126,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007778.pub2","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T17:22:26Z","timestamp":1492104146000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chlorpromazine dose for people with schizophrenia"],"prefix":"10.1002","volume":"2017","author":[{"given":"Katharine","family":"Dudley","sequence":"first","affiliation":[{"name":"University of Nottingham; Institute of Mental Health; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Utrecht University; Postbus 85500 Utrecht Netherlands 3508 GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"De Haan","sequence":"additional","affiliation":[{"name":"GGZ Noord Holland Noord; Oude Hoeverweg 10 Alkmaar Netherlands 1816 BT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,13]]},"reference":[{"issue":"2-3","key":"10.1002\/14651858.CD007778.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000117539","article-title":"Alpha-methyldopa-chlorpromazine combination in schizophrenic patients","volume":"2","author":"Chouinard","year":"1976","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cpt1970116883","article-title":"The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients","volume":"11","author":"Clark","year":"1970","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD007778.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF00412672","article-title":"Chlorpromazine in chronic schizophrenia - behavioral dose-response relationships","volume":"18","author":"Clark","year":"1970","journal-title":"Psychopharmacology [Psychopharmacologia]"},{"issue":"4","key":"10.1002\/14651858.CD007778.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archpsyc.1972.01750280047009","article-title":"Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose-response relationships","volume":"27","author":"Clark","year":"1972","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0005|cit5","first-page":"251","article-title":"EEG dose-response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking","volume":"4","author":"Serafetinides","year":"1972","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD007778.pub2-BIB0006|cit6","first-page":"35","article-title":"Neuroleptic therapy for chronic schizophrenia","volume":"33","author":"Ayd","year":"1972","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0007|cit7","first-page":"19","article-title":"Incidence and significance of chlorpromazine-induced eye changes","volume":"29","author":"Long","year":"1968","journal-title":"Diseases of the Nervous System"},{"issue":"12","key":"10.1002\/14651858.CD007778.pub2-BIB0008|cit8","first-page":"983","article-title":"A 12 year follow up study of chronic schizophrenics","volume":"33","author":"Gardos","year":"1982","journal-title":"Hospital and Community Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD007778.pub2-BIB0010|cit9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archpsyc.1968.01740040098013","article-title":"High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group","volume":"18","author":"Prien","year":"1968","journal-title":"Archives of General Psychiatry"},{"issue":"523","key":"10.1002\/14651858.CD007778.pub2-BIB0009|cit10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1192\/bjp.115.523.679","article-title":"Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication","volume":"115","author":"Prien","year":"1968","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD007778.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/archpsyc.1970.01750050080011","article-title":"Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study","volume":"23","author":"Prien","year":"1970","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0012|cit12","unstructured":"Prien RF Levine J Cole JO High dose therapy in chronic schizophrenia - trifuoperazine 121st Annual Meeting of the American Psychiatric Association; 1968 May 13-17; Boston (MA) Boston (MA) American Psychiatric Association 1968"},{"issue":"11","key":"10.1002\/14651858.CD007778.pub2-BIB0013|cit13","first-page":"739","article-title":"Indications for high dose chlorpromazine therapy in chronic schizophrenia","volume":"31","author":"Prien","year":"1970","journal-title":"Diseases of the Nervous System"},{"issue":"1","key":"10.1002\/14651858.CD007778.pub2-BIB0014|cit14","first-page":"4","article-title":"Discontinuation of chemotherapy for chronic schizophrenics","volume":"22","author":"Prien","year":"1971","journal-title":"Hospital and Community Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD007778.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0447.1978.tb06929.x","article-title":"Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine","volume":"58","author":"Wode-Helgodt","year":"1978","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD007778.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1600-0447.1977.tb00229.x","article-title":"Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients","volume":"56","author":"Wode-Helgodt","year":"1977","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD007778.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0447.1977.tb06671.x","article-title":"Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients","volume":"56","author":"Wode-Helgodt","year":"1977","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD007778.pub2-BIB0018|cit18","first-page":"203","article-title":"Different doses of clozapine and chlorpromazine in the treatment of schizophrenia clinical research","volume":"22","author":"Xu","year":"2009","journal-title":"Archives of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD007778.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1532-5415.1973.tb01683.x","article-title":"Behavioral effects of drug therapy on psychogeriatric inpatients: I. chlorpromazine and thioridazine","volume":"21","author":"Altman","year":"1973","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1192\/bjp.128.5.451","article-title":"A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients","volume":"128","author":"Andrews","year":"1976","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD007778.pub2-BIB0021|cit21","first-page":"109","article-title":"Serum chlorpromazine and prolactin levels in paranoid schizophrenic patients and clinical response. Regional Symposium of the World","volume":"2","author":"Bartko","year":"1988","journal-title":"European Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD007778.pub2-BIB0022|cit22","first-page":"103","article-title":"Does sigma receptor antagonism predict clinical antipsychotic efficacy?","volume":"27","author":"Borison","year":"1991","journal-title":"Psychopharmacology Bulletin"},{"issue":"9","key":"10.1002\/14651858.CD007778.pub2-BIB0023|cit23","first-page":"1399","article-title":"Practical considerations on treatment with antipsychotic preparations","volume":"75","author":"Caffey","year":"1975","journal-title":"Zhurnal nevropatologii i psikhiatrii imeni s. S. Korsakova"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1176\/ajp.117.11.997","article-title":"Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine","volume":"117","author":"Casey","year":"1961","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD007778.pub2-BIB0025|cit25","first-page":"485","article-title":"A comparative study of EEG changes in patients treated by risperidone, chlorpromazine and clozpine","volume":"23","author":"Chen","year":"2002","journal-title":"Journal of Qiqihar Medical College"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0026|cit26","first-page":"641","article-title":"Amenorrhea and elevated level of serum cholesterol produced by a trifluoro-methylated phenothiazine (SKF-5354-A)","volume":"20","author":"Clark","year":"April 1960","journal-title":"The Endocrine Society"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00592679","article-title":"Chlorpromazine in chronic schizophrenic women: I. Experimental design and effects at maximum point of treatment","volume":"2","author":"Clark","year":"1961","journal-title":"Psychopharmacologia"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cpt1970116883","article-title":"The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients","volume":"11","author":"Clark","year":"1970","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD007778.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/00006842-196711000-00008","article-title":"Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships","volume":"29","author":"Clark","year":"1967","journal-title":"Psychosomatic Medicine"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cpt1970116883","article-title":"The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients","volume":"11","author":"Clark","year":"1970","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD007778.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00404305","article-title":"Chlorpromazine in chronic schizophrenic women: its effect on thyroid and liver function in relation to serum cholesterol concentration","volume":"2","author":"Clark","year":"1970","journal-title":"Pharmacologia Clinica"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cpt1970116883","article-title":"The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients","volume":"11","author":"Clark","year":"1970","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD007778.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/cpt1970115680","article-title":"Molindone in chronic schizophrenia","volume":"11","author":"Clark","year":"1970","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0035|cit34","first-page":"191","article-title":"A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients","volume-title":"Pharmacokinetics of Psychoactive Drugs","author":"Clark","year":"1976"},{"issue":"3","key":"10.1002\/14651858.CD007778.pub2-BIB0034|cit35","first-page":"43","article-title":"Chlorpromazine kinetics and clinical response","volume":"14","author":"Clark","year":"1978","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD007778.pub2-BIB0036|cit36","first-page":"73","article-title":"Plasma-level studies of chlorpromazine following the administration of chlorpromazine hydrochloride and chlorpromazine embonate in chronic schizophrenics","volume":"15","author":"Cooper","year":"1973","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"2","key":"10.1002\/14651858.CD007778.pub2-BIB0037|cit37","first-page":"209","article-title":"Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs","volume":"9","author":"Crane","year":"1968","journal-title":"Agressologie"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0038|cit38","article-title":"Antipsychotic drugs. I. chlorpromazine: pharmacokinetics, plasma levels and clinical response","volume-title":"Plasma Levels of Psychotropic Drugs and Clinical Response","author":"Curry","year":"1978"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0039|cit39","first-page":"343","article-title":"Metabolism and kinetics of chlorpromazine in relation to effect","volume-title":"Antipsychotic Drugs: Pharmacodynamics and Pharmacokinetics","author":"Curry","year":"1976"},{"issue":"3","key":"10.1002\/14651858.CD007778.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02245122","article-title":"Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers","volume":"108","author":"Danion","year":"1992","journal-title":"Psychopharmacology [Psychopharmacologia]"},{"issue":"1","key":"10.1002\/14651858.CD007778.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1600-0447.1992.tb01446.x","article-title":"Effects of antipsychotic drugs on memory functions of schizophrenic patients","volume":"85","author":"Eitan","year":"1992","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0042|cit42","first-page":"269","article-title":"A controlled clinical psychiatric study of chlorpromazine","volume":"18","author":"Gibbs","year":"1957","journal-title":"Journal of Clinical and Experimental Psychopathology"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Gibbs JJ Wilkens B Lauterbach CG A controlled clinical psychiatric study of the drug chlorpromazine American Journal of Psychiatry 1956 254 5","DOI":"10.1176\/ajp.113.3.254"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0006-3223(97)00452-6","article-title":"The effects of chlorpromazine and lorazepam on abnormal antisaccade and no-saccade distractibility","volume":"44","author":"Green","year":"1998","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s002130050111","article-title":"A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam","volume":"128","author":"Green","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.2044-8295.1978.tb01656.x","article-title":"Chlorpromazine and serial reaction performance","volume":"69","author":"Hartley","year":"1978","journal-title":"British Journal of Psychology"},{"issue":"6","key":"10.1002\/14651858.CD007778.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0447.1982.tb04504.x","article-title":"ECT-chlorpromazine combination versus chlorpromazine alone in acutely schizophrenic patients","volume":"66","author":"Janakiramaiah","year":"1982","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"9","key":"10.1002\/14651858.CD007778.pub2-BIB0048|cit48","first-page":"755","article-title":"Masking of tardive dyskinesia with four times-a-day administration of chlorpromazine","volume":"38","author":"Jeste","year":"1977","journal-title":"Diseases of the Nervous System"},{"issue":"1","key":"10.1002\/14651858.CD007778.pub2-BIB0049|cit49","first-page":"45","article-title":"Vitamins B1, B6, and B12 in the adjunctive treatment of schizophrenia - further studies to examine the effect of reduction of chlorpromazine dosage","volume":"11","author":"Joshi","year":"1982","journal-title":"Journal of Orthomolecular Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD007778.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-0447.1981.tb00770.x","article-title":"Single daily dose chlorpromazine therapy in psychosis. An evaluation","volume":"64","author":"Kalyanasundaram","year":"1981","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Lehmann HE Wilson WH Deutsch M Minimal maintenance medication: effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients Comprehensive Psychiatry 1983 293 303 6136389","DOI":"10.1016\/0010-440X(83)90057-3"},{"issue":"9","key":"10.1002\/14651858.CD007778.pub2-BIB0052|cit52","first-page":"1014","article-title":"A comparison of the relative clinical efficacy of two chlorpromazine (CPZ) preparations","volume":"16","author":"Ota","year":"1974","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD007778.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0920-9964(93)90076-U","article-title":"Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study","volume":"10","author":"Pigache","year":"1993","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF01575453","article-title":"Comparison of low and high dosage procedures in chlorpromazine therapy","volume":"33","author":"Schiele","year":"1959","journal-title":"Psychiatric Quarterly"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0055|cit55","first-page":"169","article-title":"A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics","volume":"1","author":"Sukegawa","year":"2008","journal-title":"Tottori Journal of Clinical Research"},{"issue":"4","key":"10.1002\/14651858.CD007778.pub2-BIB0056|cit56","first-page":"712","article-title":"Implementation of appropriate administration of antipsychotics - measures to reduce high-dose multiple antipsychotics","volume":"71","author":"Sukegawa","year":"2013","journal-title":"Nihon Rinsho"},{"issue":"6","key":"10.1002\/14651858.CD007778.pub2-BIB0057|cit57","first-page":"696","article-title":"Measures to reduce high-dose multiple antipsychotics in Japan","volume":"114","author":"Sukegawa","year":"2012","journal-title":"Seishin Shinkeigaku Zasshi"},{"issue":"1","key":"10.1002\/14651858.CD007778.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-244X-14-103","article-title":"Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan","volume":"14","author":"Sukegawa","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD007778.pub2-BIB0059|cit59","first-page":"153","article-title":"A study on the relationship between the chlorpromazine plasma levels and clinical response to chlorpromazine administrations in the schizophrenics","volume":"27","author":"Yuan-Guang","year":"1994","journal-title":"Chinese Journal of Neurology and Psychiatry"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0060|cit60","doi-asserted-by":"crossref","unstructured":"Adams CE Bergman H Irving CB Lawrie S Haloperidol versus placebo for schizophrenia Cochrane Database of Systematic Reviews 2013 10.1002\/14651858.CD003082.pub3","DOI":"10.1002\/14651858.CD003082.pub3"},{"issue":"1","key":"10.1002\/14651858.CD007778.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000284.pub3","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Adams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0063|cit63","volume-title":"Statistical Methods in Medical Research","author":"Armitage","year":"1971"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0064|cit64","volume-title":"Schizophrenia and Public Health","author":"Barbato","year":"1998"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0065|cit65","volume-title":"Psychotropic Drug Directory 2014","author":"Bazire","year":"2014"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0067|cit67","volume-title":"British National Formulary","author":"Joint Fomulary Committee","year":"2014"},{"issue":"4","key":"10.1002\/14651858.CD007778.pub2-BIB0068|cit68","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S003329170002729X","article-title":"Antipsychotic drugs: is more worse? A meta analysis of the published randomised control trials","volume":"24","author":"Bollini","year":"1994","journal-title":"Psychological Medicine"},{"issue":"10","key":"10.1002\/14651858.CD007778.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cpt1970116883","article-title":"The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients","volume":"11","author":"Clark","year":"1970","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0022-3956(74)90071-5","article-title":"Dose equivalence of the antipsychotic drugs","volume":"11","author":"David","year":"1974","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"de Oliveira Marques L Soares B de Lima MS Trifluoperazine for schizophrenia Cochrane Database of Systematic Reviews 2004 10.1002\/14651858.CD003545.pub2","DOI":"10.1002\/14651858.CD003545.pub2"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0074|cit74","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa Cape Town 2000"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0075|cit75","unstructured":"Deeks JJ Higgins JPT Altman DG editor(s) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"Dold M Samara MT Li C Tardy M Leucht S Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders Cochrane Database of Systematic Reviews 2015 10.1002\/14651858.CD009831.pub2","DOI":"10.1002\/14651858.CD009831.pub2"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007778.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure to measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Essali A Al-Haj HN Li C Rathbone J Clozapine versus typical neuroleptic medication for schizophrenia Cochrane Database of Systematic Reviews 2009 10.1002\/14651858.CD000059.pub2","DOI":"10.1002\/14651858.CD000059.pub2"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Fenton M Rathbone J Reilly J Thioridazine for schizophrenia Cochrane Database of Systematic Reviews 2007 10.1002\/14651858.CD001944.pub2","DOI":"10.1002\/14651858.CD001944.pub2"},{"issue":"7","key":"10.1002\/14651858.CD007778.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: a systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0087|cit87","first-page":"217","volume-title":"Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0089|cit89","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0090|cit90","unstructured":"Higgins JPT Green S editor(s) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0091|cit91","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0092|cit92","doi-asserted-by":"crossref","unstructured":"Hunter R Kennedy E Song F Gadon L Irving CB Risperidone versus typical antipsychotic medication for schizophrenia Cochrane Database of Systematic Reviews 2003 10.1002\/14651858.CD000440","DOI":"10.1002\/14651858.CD000440"},{"issue":"1","key":"10.1002\/14651858.CD007778.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0095|cit95","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0096|cit96","doi-asserted-by":"crossref","unstructured":"Koch K Mansi K Haynes E Adams CE Sampson S Furtado VA Trifluoperazine versus placebo for schizophrenia Cochrane Database of Systematic Reviews 2014 10.1002\/14651858.CD010226.pub2","DOI":"10.1002\/14651858.CD010226.pub2"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Komossa K Rummel-Kluge C Schwarz S Schmid F Hunger H Kissling W Risperidone versus other atypical antipsychotics for schizophrenia Cochrane Database of Systematic Reviews 2011 10.1002\/14651858.CD006626.pub2","DOI":"10.1002\/14651858.CD006626.pub2"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Kumar A Strech D Zuclopenthixol dihydrochloride for schizophrenia Cochrane Database of Systematic Reviews 2005 10.1002\/14651858.CD005474","DOI":"10.1002\/14651858.CD005474"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"issue":"2-3","key":"10.1002\/14651858.CD007778.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0102|cit102","doi-asserted-by":"crossref","unstructured":"Leucht C Kitzmantel M Kane J Leucht S Chua WL Haloperidol versus chlorpromazine for schizophrenia Cochrane Database of Systematic Reviews 2008 10.1002\/14651858.CD004278.pub2","DOI":"10.1002\/14651858.CD004278.pub2"},{"issue":"11","key":"10.1002\/14651858.CD007778.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/j.1552-4604.1988.tb03117.x","article-title":"Does chlorpromazine produce cardiac arrhythmia via the central nervous system?","volume":"28","author":"Lipka","year":"1988","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0104|cit104","doi-asserted-by":"crossref","unstructured":"Magalh\u00e3es Pedro VS Dean O Andreazza AC Berk M Kapczinski F Antioxidant treatments for schizophrenia Cochrane Database of Systematic Reviews 2016 10.1002\/14651858.CD008919.pub2","DOI":"10.1002\/14651858.CD008919.pub2"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0106|cit106","unstructured":"Statistics on Mental Health. Factsheet Mental Health Foundation 2014"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"5","key":"10.1002\/14651858.CD007778.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/archpsyc.1970.01750050080011","article-title":"Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study","volume":"23","author":"Prien","year":"1970","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0109|cit109","doi-asserted-by":"crossref","unstructured":"Rummel-Kluge C Kissling W Leucht S Antidepressants for the negative symptoms of schizophrenia Cochrane Database of Systematic Reviews 2006 10.1002\/14651858.CD005581.pub2","DOI":"10.1002\/14651858.CD005581"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0110|cit110","doi-asserted-by":"crossref","unstructured":"Saha KB Bo L Zhao S Xia J Sampson S Zaman RU Chlorpromazine versus atypical antipsychotic drugs for schizophrenia Cochrane Database of Systematic Reviews 2016 10.1002\/14651858.CD010631.pub2","DOI":"10.1002\/14651858.CD010631.pub2"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0112|cit112","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD007778.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavacia"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0115|cit115","unstructured":"Sterne JAC Egger M Moher D editor(s) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0116|cit116","doi-asserted-by":"crossref","unstructured":"Tardy M Huhn M Kissling W Engel RR Leucht S Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia Cochrane Database of Systematic Reviews 2014 10.1002\/14651858.CD009268.pub2","DOI":"10.1002\/14651858.CD009268.pub2"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0117|cit117","doi-asserted-by":"crossref","unstructured":"Tardy M Dold M Engel RR Leucht S Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia Cochrane Database of Systematic Reviews 2014 10.1002\/14651858.CD009396.pub2","DOI":"10.1002\/14651858.CD009396.pub2"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007778.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"s7","DOI":"10.1136\/bmj.39034.609074.94","article-title":"Chlorpromazine: unlocking psychosis","volume":"334","author":"Turner","year":"2007","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Tuunainen A Wahlbeck K Newer atypical antipsychotic medication versus clozapine for schizophrenia Cochrane Database of Systematic Reviews 2000 10.1002\/14651858.CD000966","DOI":"10.1002\/14651858.CD000966"},{"issue":"5","key":"10.1002\/14651858.CD007778.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"11","key":"10.1002\/14651858.CD007778.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0006-3223(01)01252-5","article-title":"Prefrontal neurons and the genetics of schizophrenia","volume":"50","author":"Weinberger","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0122|cit122","volume-title":"Schizophrenia","author":"Weinberger","year":"2011"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0123|cit123","unstructured":"World Health Organisation The World Health Report 2001 Mental Health: New Understanding, New Hope www.who.int\/whr\/2001\/en\/"},{"key":"10.1002\/14651858.CD007778.pub2-BIB0124|cit124","unstructured":"World Health Organisation WHO Model List of Essential Medicines apps.who.int\/iris\/bitstream\/10665\/93142\/1\/EML_18_eng.pdf?ua=1"},{"issue":"7","key":"10.1002\/14651858.CD007778.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD007778.pub2-BIB0126|cit126","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007778","article-title":"Chlorpromazine dose for people with schizophrenia","author":"Liu","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007778.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T01:18:51Z","timestamp":1704763131000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007778.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,13]]},"references-count":126,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007778.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,13]]}}}